Chinese Local Pharmas See Innovative Products As Future Growth Driver - China Healthcare Investment Conference
BEIJING - Fueled by the Chinese government's latest five-year plan that will promote innovation and increase exports of finished products, Chinese domestic companies are increasing their R&D efforts to ensure future growth, companies said during the second annual China Healthcare Investment conference March 23
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.